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Objectives. To assess the relation between beta-blocker use, underlying cardiac risk, and 1-year outcome in vascular
surgery patients, including the effect of beta-blocker withdrawal.
Design. Prospective survey.
Materials. 711 consecutive peripheral vascular surgery patients from 11 hospitals in the Netherlands between May and
December 2004.
Methods. Patients were evaluated for cardiac risk factors, beta-blocker use and 1-year mortality. Low and high risk was
defined according to the Revised Cardiac Risk Index. Propensity scores for the likelihood of beta-blocker use were calculated
and regression models were used to study the relation between beta-blocker use and mortality.
Results. 285 patients (40%) received beta-blockers throughout the perioperative period (continuous users). Only 52% of
the 281 high risk patients received continuous beta-blocker therapy. Beta-blocker therapy was started in 29 and stopped in
21 patients, respectively. One-year mortality was 11%. After adjustment for potential confounders and the propensity of its
use, continuous beta-blocker use remained significantly associated with a lower 1-year mortality compared to non-users
(HR¼ 0.4; 95%CI¼ 0.2e0.7). In contrast, beta-blocker withdrawal was associated with an increased risk of 1-year mor-
tality compared to non-users (HR¼ 2.7; 95%CI¼ 1.2e5.9).
Conclusions. We demonstrated an under-use of beta-blockers in vascular surgery patients, even in high-risk patients.
Perioperative beta-blocker use was independently associated with a lower risk of 1-year mortality compared to non-use,
while perioperative withdrawal of beta-blocker therapy was associated with a higher 1-year mortality.
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Patients with peripheral vascular disease frequently
have underlying (a)-symptomatic coronary artery dis-
ease (CAD). When undergoing vascular repair they
are at increased risk of life-threatening peri- and
postoperative cardiac complications, especially myo-
cardial infarction (MI).1e3 In order to improve post-
operative outcome of non-cardiac surgery patients,
the American College of Cardiology (ACC) and the
American Heart Association (AHA) developed guide-
lines for perioperative cardiac risk evaluation and risk
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cerned, guidelines recommend beta-blocker therapy
in all high-risk patients, since several randomised
clinical trials demonstrated a significant reduction in
perioperative cardiac death or MI by such therapy.5,6
In contrast to high cardiac risk patients, evidence
in favour of beta-blocker use in patients with low or
intermediate risk is less clear.
The pathophysiology of a perioperative MI (PMI) is
not entirely clear. In patients with severe CAD, PMI
may be caused by a sustained myocardial supply/
demand imbalance due to prolonged tachycardia
and increased myocardial contractility. Beta-blockers
can restore the supply/demand mismatch through
a reduction of myocardial oxygen consumption by
decreasing sympathetic tone and myocardial contrac-
tility. At the other hand, it has been suggested thatrved.
14 S. E. Hoeks et al.sudden withdrawal of beta-blockers around the time
of peripheral vascular surgery may increase the risk
of PMI.7,8 The occurrence of withdrawal syndromes
after withdrawal of beta-blocker use in patients with
CAD have been widely reported.9e12 In contrast,
this phenomenon is still unclear in vascular surgery
patients.
Although guidelines recommend beta-blocker ther-
apy, little is known about the application of beta-
blockers in patients undergoing vascular surgery in
clinical practice. Available data suggests that beta-
blockers are underused in patients undergoing vascu-
lar repair .13e16
The objective of the study was to assess the relation
between the prescription of beta-blockers, underlying
cardiac risk, and 1-year mortality in consecutive pe-
ripheral vascular surgery patients. We were especially
interested in the effect of beta-blocker withdrawal.
Methods
Study population
Between May and December 2004, a survey of clinical
practice was conducted in 11 hospitals in the Nether-
lands. This survey was an integrated part of the infra-
structure of the survey program supported by the
Netherlands Heart Foundation in the context of
the Euro Heart Survey Programme. Five hospitals
were located in the centre part of the country, three
centres in the northern region and three in the southern
region. The participating sites included 2 small centers
(<400 beds), 5 of intermediate size (400 to 800 beds)
and 4 large centers (>800 beds). Two centres were uni-
versity hospitals, which act as tertiary referral centers.
All patients who were admitted to the vascular
surgery department of the participating hospitals
were screened. Patients undergoing peripheral vascu-
lar repair were eligible for participation in the survey.
We excluded patients below the age of 18 years.
Patients had to provide informed consent. The medi-
cal ethics committees of the participating hospitals
approved the study.
Data collection
Trained research assistants obtained data on patient
characteristics, applied diagnostic procedures, cardio-
protective treatment and the surgical procedure from
the patients’ hospital charts. All data were entered
into the electronic Case Record Form (eCRF) and
transferred regularly to the central database at Eras-
mus MC via the Internet. Data entered into theEur J Vasc Endovasc Surg Vol 33, January 2007eCRF were automatically checked for completeness,
internal consistency and accuracy. The data manage-
ment staff at Erasmus MC performed additional edit
checks. If necessary, queries were resolved with the
local research assistants.
Endpoints
This survey was designed to evaluate the application
of guidelines in patients undergoing peripheral
vascular surgery. Outcome and adverse events were
reported at 30-days and 1-year after surgery by the
local research assistants, and not adjudicated by an
independent endpoint committee. Since we realise
the survey design is susceptible to observer bias,
especially with regard to ‘‘soft’’ endpoints, we choose
the incidence of all-cause mortality at one year after
surgery as endpoint of this study.
Data analysis
We determined the cardiac risk score for each patient
in our dataset, according to the Revised Cardiac Risk
index that was developed by Lee et al.17 and one point
was assigned to each of the following characteristics:
open vascular surgery, history of ischemic heart dis-
ease, history of congestive heart failure, history of
cerebrovascular disease, insulin therapy for diabetes
mellitus and renal failure. Hypertension was recorded
if patients presented with a blood pressure 140/
90 mm Hg or if patients were medically treated
for hypertension. Diabetes Mellitus was recorded if
patients presented with a fasting glucose level
7.0 mmol/l, or in those who required treatment. Re-
nal insufficiency was recorded if patients presented
with a serum creatinine level 2.0 mg/dl or in those
who required dialysis. Obesity was defined as having
a Body Mass Index 30.
We defined four categories of beta-blocker use
(Table 1): continuous users, who used beta-blockers
throughout the in-hospital period; stoppers, who
used and subsequently stopped the beta-blocker in
the perioperative period; starters, who started the
beta-blocker postoperatively; and non-users, who
didn’t receive a beta-blocker.
Dichotomous data are described as numbers and
percentages, and continuous data are presented as
means with standard deviations (SD). Differences in
baseline characteristics between beta-blocker users
were evaluated by analysis of variances (ANOVA)
and Chi-square tests, where appropriate.
We developed a propensity score for the likelihood
of receiving continuous beta-blocker therapy, and
15Beta-blocker Withdrawal in Vascular Surgery PatientsTable 1. Definitions of beta-blocker use
Use at day
of surgery
Use at
discharge*
N In-hospital
mortality
30 day
mortality
1-year
mortality
Beta-blockers
Continuous usersy Yes Yes 285 5 (2%) 5 (2%) 17 (6%)
Stoppers Yes No 21 5 (24%) 5 (24%) 8 (38%)
Starters No Yes 29 0 (0%) 0 (0%) 3 (10%)
Non users No No 376 17 (5%) 18 (5%) 49 (13%)
* Discharge home or in-hospital death.
y For example, continuous users were defined as receiving beta-blockers at the day of surgery until the day of discharge.used applied multivariable logistic regression analysis
to calculate the propensity score. The variables in-
cluded in the model were: age, gender, obesity, smok-
ing, hypertension, arrhythmia, valvular disease,
COPD, Revised Cardiac Risk Index, statins, calcium-
channel blockers, ACE-inhibitors, angiotensin-receptor
blockers, diuretics, heparins, oral nitrates, folium acid,
antibiotics, vitamin K antagonists, antiplatelet agents.
The performance of the propensity score model was
studied with respect to discrimination and calibration.
Discrimination refers to the ability to distinguish beta-
blocker users from non-users; it was quantified by the
c-statistic. Calibration refers to whether the predicted
probability of beta-blocker use is in agreement with
the observed probability and was measured with the
Hosmer-Lemeshow goodness-of-fit-test.
The method of Kaplan-Meier was used to describe
the incidence of death over time. A log-rank test was
applied to study differences in survival between con-
tinuous users, stoppers, starters and non-users. These
relations were further evaluated by multivariable
Cox’ proportional hazard regression analysis, with
adjustment for confounders and propensity score.
All potential confounders (age, gender, obesity,
smoking, hypertension, arrhythmia, valvular disease,
COPD and the Revised Cardiac Risk Index) were
entered in the multivariable model to ensure giving
an as unbiased as possible estimate for the relation
between beta-blocker use and one-year mortality.
Crude and adjusted Odds and Hazard ratios are re-
ported with corresponding 95% confidence intervals
(CI). For all tests, a p-value <0.05 (two-sided) was
considered significant. All statistical analyses were
performed using SPSS statistical software.
Results
Of the total of 711 patients, 285 patients (40%) re-
ceived a beta-blocker throughout the perioperative
period, i.e. the continuous users (Table 1). Beta-
blocker therapy was started in 29 patients and
stopped in 21 patients, respectively. In 19% of those
21 stoppers the beta-blocker was stopped on the dayof intervention. Overall, 376 patients (53%) didn’t
use a beta-blocker at all.
Table 2 shows the baseline characteristics according
to the four beta-blocker categories. The mean age of
the study population was 67 years, and 70% were
men. Half of patients underwent an endovascular
procedure (n¼ 354), 328 patients (46%) had open sur-
gery and 29 patients (4%) underwent carotid endarter-
ectomy. The non-users represent a low cardiac risk
group with 71% having no or only one risk factor
according to the Revised Cardiac Risk Index. In contrast,
about half of the continuous users (51%) and stoppers
(52%) had 2 or more risk factors. As shown in Fig. 1,
continuous beta-blocker was positively associated with
the Revised Cardiac Risk Index. However, only 52% of
patients at high cardiac risk, with 2 or more risk factors,
received continuous beta-blocker therapy.
Within the propensity score analysis, baseline variab-
les that significantly predicted continuous beta-blocker
therapy were hypertension (OR¼ 1.5 (95%CI¼ 1.1e
2.2)), and the Revised Cardiac Risk Index (1: OR¼ 1.8
(95%CI¼ 1.1e2.9); 2: OR¼ 3.0 (95%CI¼ 1.8e4.9); 3:
OR¼ 1.6 (95%CI¼ 0.7e3.2)). According to medical ther-
apy, statin therapy (OR¼ 2.9 (95%CI¼ 2.0e4.1)), calcium
antagonists therapy (OR¼ 1.5 (95%CI¼ 1.0e2.2)), hepa-
rin therapy (OR¼ 1.7 (95%CI¼ 1.2e2.4)), andoral nitrate
therapy (OR¼ 2.6 (95%CI¼ 1.4e4.8)) were all significant
predictors of continuous beta-blocker prescription. The
c-statistic of the propensity score was 0.75. Calibration
with use of the Hosmer and Lemeshow test gave a
non-significant outcome.
As shown on the Kaplan-Meier curve (Fig. 2), not
receiving beta-blocker therapy was associated with
a high mortality rate but withdrawal of beta-blocker
therapy was associated with an even worse survival.
Log rank test gave a significant overall difference in
mortality among the different beta-blocker categories
( p< .001).
Postoperative in-hospital mortality occurred in 27
patients (4%) and at 1 year follow-up total mortality
was 11% of which 21% died of cardiovascular causes.
Table 3 shows the univariable and multivariable
associations between beta-blocker use and 1-yearEur J Vasc Endovasc Surg Vol 33, January 2007
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Continuous
users (n¼ 285)
Stoppers
(n¼ 21)
Starters
(n¼ 29)
Non-users
(n¼ 376)
P-value*
Demographics
Mean age (SD) 67 9 66 11 68 9 72 11 Ns
Male gender 209 (73) 19 (91) 24 (83) 244 (65) .006
Cardiovascular history
Angina pectoris 62 (22) 1 (5) 4 (14) 32 (9) <.001
Myocardial infarction 66 (23) 4 (19) 5 (17) 31 (8) <.001
Heart failure 15 (6) 2 (12) 1 (4) 19 (6) Ns
Stroke or tia 59 (21) 3 (14) 6 (21) 55 (15) Ns
Arrhythmia 37 (13) 1 (5) 3 (10) 36 (10) Ns
Valvular disease 25 (9) 3 (14) 3 (10) 19 (5) Ns
Previous revascularisation 68 (24) 2 (10) 9 (31) 37 (10) <.001
Clinical risk factors
Obesity 41 (14) 1 (5) 0 35 (9) .030
Current smoker 95 (33) 7 (33) 11 (38) 143 (38) Ns
Hypertension 135 (47) 7 (33) 10 (34) 121 (32) .001
Diabetes Mellitus 64 (23) 3 (14) 8 (28) 74 (20) Ns
Renal insufficiency 22 (8) 3 (14) 1 (3) 25 (7) Ns
COPD 39 (14) 5 (24) 3 (10) 54 (14) Ns
Surgical procedure <.001
Endovascular 131 (46) 2 (9) 10 (34) 211 (56)
Carotid endarterectomy 16 (6) 1 (5) 2 (7) 10 (3)
Open 138 (48) 18 (86) 17 (59) 155 (41)
Revised Cardiac Risk Indexy <.001
0 44 (15) 1 (5) 4 (14) 138 (37)
1 95 (33) 9 (43) 11 (38) 128 (34)
2 119 (42) 7 (33) 10 (35) 85 (22)
3 27 (10) 4 (19) 4 (14) 25 (7)
COPD, chronic obstructive pulmonary disease.
Ns, not significant.
* Overall difference between groups.
y Variables included in the Revised Cardiac Risk Index; open surgical procedure, ischaemic heart disease, history of congestive heart
failure, history of cerebrovascular disease, insulin therapy for diabetes mellitus and renal failure).mortality. Continuous beta-blocker use in the peri-
operative period remained an independent predictor
for one-year survival (HR¼ 0.3 (95%CI¼ 0.2e0.6)).
In contrast, perioperative withdrawal of beta-blockers
was independently associated with an increasing risk
of one year mortality (HR¼ 2.6 (95%CI¼ 1.2e5.6))
compared to non-use. When the propensity score
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Fig. 1. Continuous beta-blocker use by the Revised Cardiac
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Fig. 2. Kaplan-Meier estimate of 1-year all cause mortality,
stratified according to the use of beta-blockers.
17Beta-blocker Withdrawal in Vascular Surgery PatientsTable 3. Multivariable associations of beta-blocker use and 1-year mortality
Unadjusted Adjusted for confounders* Adjusted for confounders and
propensity scorey
HR 95% CI HR 95% CI HR 95% CI
Beta-blocker use
No use Reference Reference
Reference
Continuous 0.4 0.3e0.8 0.3 0.2e0.6 0.4 0.2e0.7
Stoppers 3.7 1.8e7.9 2.6 1.2e5.6 2.7 1.2e5.9
Starters 0.8 0.2e2.4 0.6 0.2e1.9 0.6 0.2e1.9
C-index 0.63 0.80 0.81
* Adjusted for age, gender, obesity, smoking, hypertension, arrhythmia, valvular disease, COPD and the Revised Cardiac Risk Indexz.
y Variables included in the propensity score model were: age, gender, arrhythmia, valvular disease, obesity, smoking, hypertension, copd,
Revised Cardiac Risk Indexz, statins, calcium-channel blockers, ACE-inhibitors, angiotensin-receptor blockers, diuretics, heparins, oral
nitrates, folium acid, antibiotics, vitamin K antagonists, antiplatelet agents.was included in the model with all the covariates to
adjust also for the chance of prescription of beta-
blockers, the effect of continuous beta-blocker therapy
and withdrawal was comparable to the analysis
adjusted for only covariates.
Discussion
Guidelines on perioperative care recommend that
high cardiac risk patients should receive a beta-
blocker.4 The present survey results of beta-blocker
use in daily clinical practice, however, provide evi-
dence for an underuse of beta-blockers in vascular
surgery, even in patients at high cardiac risk. Contin-
uous beta-blocker use is associated with a lower risk
of mortality, while an adverse effect of perioperative
withdrawal of beta-blockers was observed.
The survey shows a clear relationship between
beta-blocker use and cardiac risk stratification accord-
ing to the Revised Cardiac Risk Index: the higher the
cardiac risk, the higher the prescription rate of beta-
blockers. These results are in line with the guidelines
which recommend beta-blocker therapy in especially
high-risk patients. However, improvement is neces-
sary because still a sizeable proportion of patients
are not treated according to the guidelines. Identified
barriers in following clinical guidelines, such as lack
of awareness, lack of agreement with the guidelines,
difficult to use (not concise enough), and so on, might
partly explain the limited adherence to guidelines in
clinical practice.18,19
Our study demonstrated that continuous beta-
blocker use during the perioperative period is inde-
pendently associated with a better postoperative
outcome. This result is partly in contrast to the study
of Lindenauer who assessed the association between
the perioperative use of beta-blockers and in-hospitalmortality and found that beta-blockers were harmful
in low-risk patients, neutral in patients at intermedi-
ate risk, and beneficial in high-risk patients.20 How-
ever, this observed adverse effect in the low risk
population has been questioned because beta-blockers
in may have been prescribed in response to a cardiac
complication, rather to prevent one.21 Further rando-
mised controlled trials are needed to assess the bene-
fits of beta-blocker in patients at low or intermediate
cardiac risk.
Patients in whom beta-blockers were periopera-
tively stopped have an increased risk of mortality com-
pared to both continuous users and non-users. This
finding clearly reveals the high risk of beta-blocker
withdrawal. Similar results were found by Shammash
et al.who reported that discontinuing beta-blockers im-
mediately after surgerymay increase the risk of postop-
erative cardiovascular morbidity and mortality.7
However, the sample size of this study was very small.
A possible mechanism for the explanation of the
observed withdrawal phenomenon is that exposure to
a beta-blocker produces an increased number of post-
synaptic beta-receptors and subsequent withdrawal is
likely to result in a state of hypersensitivity.12 Continu-
ation of beta-blocker therapy is very important and if
oral intake is impossible early after surgery intra-
venous administration is a good alternative.
This study clearly reveals the need for more aware-
ness of routine and continued beta-blocker therapy in
the peri- and post-operative period. To improve this
awareness, protocols could be developed and imple-
mented in clinical practice.22,23 Future surveys are
important to assess improvement of beta-blocker
therapy over time, as shown in the comparison of
Euroaspire I and II, and to explore reasons for discon-
tinuing recommended treatment strategies.24
An important limitation of this observational study
is that the use of beta-blockers was not randomisedEur J Vasc Endovasc Surg Vol 33, January 2007
18 S. E. Hoeks et al.and therefore subject to confounding by indication.
However, giving the evidence supporting the adverse
effects of beta-blocker withdrawal, a randomised trial
of beta-blocker withdrawal may be considered uneth-
ical. Propensity analysis was performed to adjust as
much as possible for the bias inherent in the decision
about beta-blocker therapy.25 Another limitation of
this study is the small number of patients who
stopped beta-blocker therapy. Further research with
more patients is necessary to confirm our findings.
In conclusion, this study demonstrates an underuse
of beta-blocker therapy in patients undergoing vascu-
lar repair, even in patients at high cardiac risk. Contin-
ued beta-blocker use in those patients is associated
with a lower risk of mortality. However, withdrawal
of beta-blocker therapy prior to surgery is accompa-
nied with a higher risk of mortality compared to
non-users. Further research is necessary in this area
and subsequent effective strategies are needed to
implement guidelines and results of clinical trials in
clinical practice.
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